Seminars in Oncology
Volume 32, Issue 3 , Pages 315-328 , June 2005

Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy

  • Takeshi Isobe
  • ,
  • Roy S. Herbst
  • ,
  • Amir Onn

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Amir Onn, MD, Department of Pulmonary Medicine, Unit 403, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030

  • Image Result

    Representative samples of immunofluorescent histology of CD31 and EGFR in human adenocarcinoma of the lung. (A) Double-labeling for CD31 and EGFR to study expression of receptor on tumor-associated en

    Representative samples of immunofluorescent histology of CD31 and EGFR in human adenocarcinoma of the lung. (A) Double-labeling for CD31 and EGFR to study expression of receptor on tumor-associated endothelial cells. (B) EGFR expression on tumor cells. Red: CD31+ endothelial cells; green: EGFR+ cells; yellow: EGFR+ endothelial cells (arrows); blue: nuclear staining (original magnification, ×400). In this particular tumor, both tumor cells and tumor-associated endothelial cells express EGFR.

  • Image Result
    Immunohistochemical analysis of growth factor and angiogenesis-related genes in primary and metastatic tumors. The expression patterns differ by histologic type and metastasis site.

    Immunohistochemical analysis of growth factor and angiogenesis-related genes in primary and metastatic tumors. The expression patterns differ by histologic type and metastasis site.

  • Image Result
    New paradigm for the use of biologic therapy for advanced lung cancer.

    New paradigm for the use of biologic therapy for advanced lung cancer.

PII: S0093-7754(05)00086-2

doi: 10.1053/j.seminoncol.2005.02.016

Seminars in Oncology
Volume 32, Issue 3 , Pages 315-328 , June 2005